Hospira highlights its success of biosimilar offering

May 3, 2013 10:08 AM

hospira

Hospira, Inc. announced an important milestone, commemorating five years of providing biosimilars to the European market and delivery of more than five million doses of high-quality biosimilar medicines at a lower cost to patients in Europe and Australia.

Biosimilars were an important industry topic at the BIO International Convention in Chicago last week, with multiple sessions devoted to topics such as biosimilar regulatory approval, manufacturing and market formation.

“Bringing biosimilars to the United States is the next major step toward reducing costs for the U.S. healthcare system,” said Thomas Moore, president, U.S., Hospira. “As the first U.S. company to market biosimilars globally, Hospira will build on our track record of success to introduce biosimilars in the United States and increase access for Americans to high-quality biologic medications that treat severe and life-threatening diseases.”

Retacrit, Hospira’s first biosimilar, was launched in Europe in early 2008 and on the market for about 5 years in the EU. A total of more than 1,600 patients were studied to support intravenous and subcutaneous administration of the product. Retacrit is a recombinant human erythropoietin, or “EPO biosimilar.” Hospira’s second marketed biosimilar product is Nivestim, a biosimilar version of filgrastim (G-CSF). Nivestim entered the European market in 2010 and the Australian market in 2011.

Thomas Moore said: “Biosimilars have come to stay in Europe, and we’re very pleased with the progress we are seeing.”

Hospira is currently conducting a Phase III U.S. clinical trial program with its biosimilar version of EPO. Hospira’s broad biosimilars pipeline, including products it shares with South Korean partner Celltrion, includes 11 products and is one of the largest in the industry.

In 2012, Hospira filed for European approval of a biosimilar version of infliximab, a treatment for auto-immune diseases, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis and psoriasis. Hospira also has a biosimilar version of trastuzumab, in clinical studies.

 

Source: Hospira press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!